Tapentadol is a prescription opioid pain reliever used to treat mild to extreme pain. Tapentadol is also used to treat diabetic peripheral neuropathy-related neuropathic pain. It is legally available on prescription and is commonly used to treat chronic, acute, and cancer-related pain in patients. Nucynta ER is the first and only long-acting opioid analgesic approved by the FDA in the United States for the treatment of nociceptive and neuropathic pain associated with diabetic peripheral neuropathy (Learn about the reasons for Tapentadol Market growth in the Middle East).
In the Middle East, opioids such as fentanyl, morphine, oxycodone, and pethidine are widely used to treat pain-related conditions such as cancer and diabetic neuropathy. These opioids provide powerful analgesic properties yet are extremely addictive, while Tapentadol is moderately addictive and has better degrees of protection and effectiveness. Tapentadol may prove to be a viable pain relief option in the Middle East, where opioid misuse is a problem. The only patented medication for Tapentadol is Nucynta extended-release tablets. These are some of the reasons affecting the adoption of Tapentadol in the Middle East including the increasing incidence of pain-related diseases such as cancer and diabetic neuropathy in the area, as well as the absence of appropriate alternative treatment for the control of neuropathic pain. Also, the easy availability of Tapentadol 100 mg online adds to the list of reasons for its market growth.
During the forecast era, the Middle East tapentadol market is expected to rise due to an increase in the incidence of cancer and diabetic neuropathy. The malfunction of a lesion of the central or peripheral nervous system is the principal cause of neuropathic pain. Furthermore, it is a progressive disease with complicated pathophysiology. In general, NUCYNTA ER (tapentadol) is used to relieve neuropathic pain where the pain is extreme enough to require frequent tapentadol, as well as long-term opioid therapy where other treatments are insufficient.
There is little evidence that oral tramadol has a substantial pain-relieving effect in patients with extreme to mild neuropathic pain, while tapentadol’s primary use is to relieve diabetic neuropathic pain. Some opioids, such as fentanyl, oxycodone, tramadol, and oxymorphone, are not as effective in treating neuropathic pain as tapentadol.
If the patent holder restructures product sales worldwide, the Middle East tapentadol market is expected to gain substantial momentum. The Middle East tapentadol market is expected to expand with the support of regulatory bodies in the region and increased accessibility to tapentadol. Tapentadol import opportunities have been severely limited due to the lack of a large distribution system in the Middle East. This opens up a lot of doors for local companies to work with the drug patent holder to set up a sales chain.
Multidrug therapy does not always work with cancer-related neuropathic pain. To relieve such extreme pain without the use of adjuvant analgesics, new medications are needed. Tapentadol is a novel drug that acts as an opioid agonist as well as a noradrenaline reuptake inhibitor.
Answer:- One of the major drivers projected to drive demand growth over the forecast period is the rising incidence of pain-related diseases such as cancer and diabetic neuropathy.
Answer:- Over the projected period, the Middle East tapentadol demand is projected to expand at a CAGR of 6.1%.